MedTrace Logo

Persistence of Physical Activity in People With Type 2 Diabetes Over Time.

NCT05661799 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2022-12-22

No results posted yet for this study

Summary

Many programmes exist to enable patients to engage in physical activity, but it is clear that the objectives are often not achieved in terms of quality, quantity or intensity of practice. In this study, the aim is to find alternatives, assuming that strengthening patients' self-efficacy, meeting their basic needs and increasing their level of hope will have an impact on their motivation to practice, which in turn will have an impact on their actual practice. The aim is to develop and implement an innovative intervention programme and to identify the interactions between the variables that are assumed to predict engagement in practice.

Conditions

  • Diabetes Mellitus, Type 2
  • Physical Activity
  • Psychological

Interventions

BEHAVIORAL

Intervention Group

The programme is a PA programme consisting of one weekly session for 12 weeks. The one hour of PA is supplemented by two 15-minute periods. At the end of each session, a PA challenge and a positive reinforcement exercise are proposed for the coming week. At the beginning of the next session, the facilitator has a dedicated time to give feedback on these challenges (successes and difficulties encountered). At the end of each session, the facilitator explains the theme of the next challenge and exercise. For the challenge, three options are proposed. Each participant chooses the option he/she prefers. Positive reinforcement exercises are also offered in the same way. They aim to strengthen motivation, hope and the sense of self-efficacy (SEP). In addition to these two 15-minute sessions, participants are offered a one-and-a-half hour group session for information and experience sharing. The aim of this session is to discuss different themes.

BEHAVIORAL

Control Group

The programme is a PA programme consisting of one weekly session for 12 weeks.

Sponsors & Collaborators

  • Siel Bleu

    lead OTHER

Principal Investigators

  • Elise Maudet-Coulomb, Ms · Université de Lorraine, EA 4360 APEMAC, Metz, France

  • Charles Martin-Krumm, PhD · Université de Lorraine, EA 4360 APEMAC, Metz, France

  • Jean-Christophe Mino, PhD · Institut de recherche Siel Bleu, Paris France

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-09
Primary Completion
2023-04-30
Completion
2023-04-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05661799 on ClinicalTrials.gov